CN104136399B - 泛素活化酶的吡唑并嘧啶基抑制剂 - Google Patents

泛素活化酶的吡唑并嘧啶基抑制剂 Download PDF

Info

Publication number
CN104136399B
CN104136399B CN201380009784.8A CN201380009784A CN104136399B CN 104136399 B CN104136399 B CN 104136399B CN 201380009784 A CN201380009784 A CN 201380009784A CN 104136399 B CN104136399 B CN 104136399B
Authority
CN
China
Prior art keywords
pyrimidin
pyrazolo
methyl ester
acid
sulfamic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380009784.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104136399A (zh
Inventor
鲁尚·阿弗罗泽
因杜·T·巴拉坦
杰弗里·P·恰瓦利
保罗·E·弗莱明
杰弗里·L·戈兰
马里奥·吉拉德
史蒂文·P·兰斯顿
弗朗索瓦·R·苏西
王楚秦
叶迎春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN104136399A publication Critical patent/CN104136399A/zh
Application granted granted Critical
Publication of CN104136399B publication Critical patent/CN104136399B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380009784.8A 2012-02-17 2013-02-14 泛素活化酶的吡唑并嘧啶基抑制剂 Active CN104136399B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17
US61/600,070 2012-02-17
PCT/US2013/026113 WO2013123169A1 (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Publications (2)

Publication Number Publication Date
CN104136399A CN104136399A (zh) 2014-11-05
CN104136399B true CN104136399B (zh) 2018-08-07

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380009784.8A Active CN104136399B (zh) 2012-02-17 2013-02-14 泛素活化酶的吡唑并嘧啶基抑制剂

Country Status (30)

Country Link
US (4) US9290500B2 (https=)
EP (3) EP3536692B1 (https=)
JP (1) JP6122877B2 (https=)
KR (1) KR20140123104A (https=)
CN (1) CN104136399B (https=)
AR (1) AR092797A1 (https=)
BR (1) BR112014020365B1 (https=)
CA (1) CA2864672C (https=)
CL (1) CL2014002181A1 (https=)
CO (1) CO7071135A2 (https=)
CR (1) CR20140380A (https=)
DO (1) DOP2014000187A (https=)
EA (1) EA035020B1 (https=)
EC (1) ECSP14019113A (https=)
ES (1) ES2739150T3 (https=)
GE (1) GEP201706687B (https=)
HK (1) HK1201817A1 (https=)
IL (1) IL234016A0 (https=)
MA (1) MA35932B1 (https=)
MX (1) MX352963B (https=)
NZ (1) NZ628969A (https=)
PE (1) PE20142244A1 (https=)
PH (1) PH12014501832A1 (https=)
SG (2) SG10201606581RA (https=)
TN (1) TN2014000351A1 (https=)
TW (1) TWI593688B (https=)
UA (1) UA116534C2 (https=)
UY (1) UY34629A (https=)
WO (1) WO2013123169A1 (https=)
ZA (1) ZA201406103B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
JP2015524442A (ja) 2012-08-03 2015-08-24 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Uba6のインドール置換ピロロピリミジニル阻害剤
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
TW201628621A (zh) 2014-10-29 2016-08-16 千禧製藥公司 泛素活化酶抑制劑及輻射之施用
US20180133221A1 (en) * 2014-10-29 2018-05-17 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
US11155560B2 (en) 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023021498A1 (en) * 2021-08-16 2023-02-23 Moya Bio Ltd. Fused azole and furan based nucleoside analogs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524662A (ja) 2002-02-28 2005-08-18 ビオタ インコーポレーティッド ヌクレオシド5’−一リン酸模倣物およびこれらのプロドラッグ
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ES2285164T3 (es) 2002-09-04 2007-11-16 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
PT1848718E (pt) 2005-02-04 2012-10-11 Millennium Pharm Inc Inibidores de enzimas de activação e1
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
KR101450535B1 (ko) 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 E1 활성화 효소의 억제제
WO2007099021A1 (en) * 2006-02-28 2007-09-07 Sez Ag Device and method for liquid treating disc-like articles
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EA201501088A1 (ru) * 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
TWI519508B (zh) 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
WO2009042013A1 (en) 2007-08-02 2009-04-02 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
SG11201400102WA (en) 2011-08-24 2014-03-28 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
JP2015524442A (ja) 2012-08-03 2015-08-24 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Uba6のインドール置換ピロロピリミジニル阻害剤
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso

Also Published As

Publication number Publication date
US9290500B2 (en) 2016-03-22
US20170217968A1 (en) 2017-08-03
SG10201606581RA (en) 2016-09-29
US20130217682A1 (en) 2013-08-22
KR20140123104A (ko) 2014-10-21
IL234016A0 (en) 2014-09-30
SG11201404757WA (en) 2014-09-26
GEP201706687B (en) 2017-06-26
HK1201817A1 (en) 2015-09-11
ECSP14019113A (es) 2015-09-30
WO2013123169A1 (en) 2013-08-22
US9796725B2 (en) 2017-10-24
PE20142244A1 (es) 2015-01-07
EP2814791A4 (en) 2015-08-19
US20160244455A1 (en) 2016-08-25
TW201345909A (zh) 2013-11-16
BR112014020365B1 (pt) 2023-02-23
EA201400831A1 (ru) 2014-12-30
AR092797A1 (es) 2015-05-06
ZA201406103B (en) 2017-11-29
CA2864672C (en) 2018-01-09
MX2014009944A (es) 2014-11-10
PH12014501832A1 (en) 2014-11-17
US20170369499A1 (en) 2017-12-28
US10202389B2 (en) 2019-02-12
CR20140380A (es) 2014-10-28
TWI593688B (zh) 2017-08-01
ES2739150T3 (es) 2020-01-29
EP2814791A1 (en) 2014-12-24
EP3173413A1 (en) 2017-05-31
MX352963B (es) 2017-12-15
UY34629A (es) 2013-09-02
EP3536692A1 (en) 2019-09-11
EP3173413B1 (en) 2019-05-01
JP6122877B2 (ja) 2017-04-26
DOP2014000187A (es) 2014-10-15
NZ628969A (en) 2017-03-31
CL2014002181A1 (es) 2014-12-12
TN2014000351A1 (en) 2015-12-21
CO7071135A2 (es) 2014-09-30
BR112014020365A2 (pt) 2020-12-22
CA2864672A1 (en) 2013-08-22
CN104136399A (zh) 2014-11-05
US20140088096A9 (en) 2014-03-27
EP3536692B1 (en) 2021-04-07
EA035020B1 (ru) 2020-04-17
MA35932B1 (fr) 2014-12-01
UA116534C2 (uk) 2018-04-10
JP2015508775A (ja) 2015-03-23
US9663525B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
CN104136399B (zh) 泛素活化酶的吡唑并嘧啶基抑制剂
TWI510486B (zh) E1活化酶之抑制劑
JP2015508775A5 (https=)
FR3037956A1 (https=)
WO2013028832A2 (en) Inhibitors of nedd8-activating enzyme
US9156853B2 (en) AKT inhibitor compounds for treatment of cancer
TW202204351A (zh) 具有大環結構的化合物及其用途
WO2023165570A1 (zh) 环烷基或杂环基取代的杂芳基化合物及其组合物及用途
CN114369097B (zh) 杂芳环类AhR抑制剂
HK1238244A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20211110

Address after: Osaka, Japan

Patentee after: Takeda Pharmaceutical Industry Co., Ltd

Address before: Massachusetts, USA

Patentee before: Millenum pharmaceuticals